Blood Pressure Management in Acute Stroke

Blood Pressure Targets

The European Society of Cardiology recommends treating blood pressure only if it exceeds 220/120 mmHg in patients with thrombotic (ischemic) stroke not receiving thrombolysis, and actively lowering blood pressure to a target of 140 mmHg systolic in patients with hemorrhagic stroke 1, 2

For patients not receiving thrombolysis or thrombectomy, the American Heart Association suggests not treating blood pressure unless it exceeds 220/120 mmHg, due to permissive hypertension being the standard approach for the first 48-72 hours 1, 2
If blood pressure is ≥220/120 mmHg, the American Stroke Association recommends lowering blood pressure carefully by approximately 15% (not more than 25%) over the first 24 hours 3, 4
The rationale for this approach is that cerebral autoregulation is impaired in acute stroke, making cerebral perfusion directly dependent on systemic blood pressure, and aggressive lowering can extend the infarct 1, 2

Before thrombolysis, the American Heart Association recommends lowering blood pressure to <185/110 mmHg 3, 4, 2
After thrombolysis, the European Stroke Organisation suggests maintaining blood pressure <180/105 mmHg for at least 24 hours 3, 1, 4
The preferred agents for blood pressure management are labetalol 10-20 mg IV over 1-2 minutes (may repeat) or nicardipine 5 mg/hr IV infusion 5, 2

The European Society of Cardiology recommends initiating or restarting antihypertensive therapy if blood pressure remains ≥140/90 mmHg in stable patients after 3 days post-stroke, for long-term secondary prevention 1, 2

The American Heart Association recommends targeting a systolic blood pressure of 140 mmHg (achieved range typically 140-160 mmHg) if initial systolic blood pressure is 150-220 mmHg in patients with acute intracerebral hemorrhage 1
Initiation of treatment within 6 hours of symptom onset can reduce hematoma expansion 1

The European Stroke Organisation suggests avoiding excessive acute drops in systolic blood pressure >70 mmHg, as this may cause acute renal injury and early neurological deterioration 1, 2

The American Stroke Association recommends not treating blood pressure <220/120 mmHg in acute ischemic stroke (unless receiving thrombolysis), as this is ineffective and potentially harmful 1, 2
The European Society of Cardiology suggests not lowering blood pressure rapidly or aggressively, using easily titrated IV agents and avoiding precipitous falls 3, 4
The American Heart Association recommends not forgetting to restart antihypertensive medications after 3 days in patients with pre-existing hypertension 1, 2
The European Stroke Organisation suggests not using the same blood pressure targets for ischemic and hemorrhagic stroke, as they require opposite approaches in the acute phase 1

The European Society of Cardiology recommends immediate blood pressure lowering (within 6 hours of symptom onset) to a systolic target of 140-160 mmHg in patients with intracerebral hemorrhage presenting with systolic BP ≥150 mmHg, which corresponds to maintaining diastolic BP <105 mmHg. 6

Avoid excessive acute drops in systolic BP >70 mmHg from initial levels within 1 hour of commencing treatment, as this increases risk of acute renal injury and early neurological deterioration. 6
For patients presenting with systolic BP ≥220 mmHg, the same systolic target of 140-160 mmHg applies, but the rate of reduction must be controlled to avoid precipitous drops. 6

Intravenous labetalol or nicardipine are the preferred agents for blood pressure control in acute hemorrhagic stroke, allowing for precise titration to avoid excessive drops. 6

Treatment must be initiated within 6 hours of symptom onset to effectively reduce hematoma expansion and improve functional outcomes. 6

In ischemic stroke not receiving thrombolysis, diastolic BP is only treated if >120 mmHg, whereas in hemorrhagic stroke, active reduction begins at much lower thresholds. 7

Do not reduce blood pressure too rapidly (>70 mmHg drop in systolic BP within 1 hour), as this increases risk of renal complications without additional benefit. 6